We are live on ! Find out more
BI

BVF Inc Portfolio holdings

AUM $3.91B
1-Year Est. Return 304.52%
This Fund
S&P 500
This Quarter Est. Return
+19.15%
1 Year Est. Return
+304.52%
3 Year Est. Return
+591.72%
5 Year Est. Return
+1,391.92%
10 Year Est. Return
+28,184.58%
AUM
$2.8B
AUM Growth
+$346M
Cap. Flow
-$15.3M
Cap. Flow %
-0.55%
Top 10 Hldgs %
76.91%
Holding
52
New
1
Increased
6
Reduced
7
Closed
8

Top Buys

Rank Stock Value
1
IMCR icon
Immunocore
IMCR
+$31.8M
2
PTGX icon
Protagonist Therapeutics
PTGX
+$30.5M
3
CBIO
Crescent Biopharma
CBIO
+$27.3M
4
KYMR icon
Kymera Therapeutics
KYMR
+$11.7M
5
VSTM icon
Verastem
VSTM
+$8.17M

Top Sells

Rank Stock Value
1
LKFT
Lakefront Biotherapeutics American Depositary Shares
LKFT
+$36.5M
2
VERV
Verve Therapeutics
VERV
+$31.6M
3
ITOS
iTeos Therapeutics
ITOS
+$18.4M
4
XOMA
Xoma
XOMA
+$9.41M
5
THRD
Third Harmonic Bio
THRD
+$8.23M

Sector Composition

Rank Sector Weight
1 Healthcare 99.98%
2 Miscellaneous 0.02%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
ELDN icon
26
Eledon Pharmaceuticals
ELDN
$219M
$17.1M 0.61%
6,293,282
– –
ANNX icon
27
Annexon
ANNX
$747M
$16.8M 0.6%
7,000,000
– –
PVLA
28
Palvella Therapeutics
PVLA
$2.21B
$15.7M 0.56%
696,555
– –
EPIX
29
DELISTED
ESSA Pharma
EPIX
$14.9M 0.53%
8,748,629
– –
RPTX
30
DELISTED
Repare Therapeutics
RPTX
$14.4M 0.51%
10,333,600
– –
VSTM icon
31
Verastem
VSTM
$660M
$14.1M 0.5%
3,404,425
+1,303,957
+62% +$8.17M
RAPT
32
DELISTED
RAPT Therapeutics
RAPT
$9.24M 0.33%
1,154,692
-3
-0% -$23
FBRX
33
DELISTED
Forte Biosciences
FBRX
$7.61M 0.27%
588,344
-5,938
-1% -$51.1K
TCRX icon
34
TScan Therapeutics
TCRX
$22.4M
$7.58M 0.27%
5,226,074
+336,600
+7% +$486K
IMA
35
ImageneBio Inc
IMA
$58.8M
$5.37M 0.19%
333,880
– –
IMUX icon
36
Immunic
IMUX
$142M
$5.34M 0.19%
765,297
-125,000
-14% -$1.15M
MOLN
37
Molecular Partners
MOLN
$154M
$5.19M 0.19%
1,353,968
– –
AVTX icon
38
Avalo Therapeutics
AVTX
$880M
$5.13M 0.18%
1,028,049
-8,630
-0.8% -$40.3K
IVA
39
Inventiva
IVA
$900M
$2.14M 0.08%
686,040
– –
TENX icon
40
Tenax Therapeutics
TENX
$71.5M
$1.98M 0.07%
339,549
– –
SABS icon
41
SAB Biotherapeutics
SABS
$315M
$1.61M 0.06%
917,826
– –
OVID icon
42
Ovid Therapeutics
OVID
$529M
$1.27M 0.05%
3,853,818
– –
ENGNW icon
43
enGene Therapeutics Warrants
ENGNW
$586K 0.02%
945,402
– –
NCEL
44
NewcelX Ltd
NCEL
$19.4M
$417K 0.01%
14,368
– –
ALLK
45
DELISTED
Allakos
ALLK
– –
-16,552,417
Closed -$3.77M
CTMX icon
46
CytomX Therapeutics
CTMX
$617M
– –
-5,228,461
Closed -$3.32M
LKFT
47
Lakefront Biotherapeutics American Depositary Shares
LKFT
$1.83B
– –
-1,454,422
Closed -$36.5M
ITOS
48
DELISTED
iTeos Therapeutics
ITOS
– –
-3,075,000
Closed -$18.4M
NAMS icon
49
NewAmsterdam Pharma
NAMS
$2.58B
– –
-59,065
Closed -$1.21M
THRD
50
DELISTED
Third Harmonic Bio
THRD
– –
-2,372,933
Closed -$8.23M
1
2
3

Similar funds

LFCM
Long Focus Capital Management San Juan, Puerto Rico $3.91B AUM 12.68% 1-Year Est. Return
DCM
DME Capital Management New York $3.91B AUM 36.1% 1-Year Est. Return
LNC
Lincoln National Corp Radnor, Pennsylvania $3.91B AUM 14.77% 1-Year Est. Return
GL
GTCR LLC Chicago, Illinois $3.91B AUM 14.64% 1-Year Est. Return
AC
Anther Capital Hong Kong $3.91B AUM
FFGIM
Founders Fund Growth II Management San Francisco, California $3.9B AUM
AIM
ARGA Investment Management Stamford, Connecticut $3.92B AUM 35.93% 1-Year Est. Return
LCM
Laurion Capital Management New York $3.9B AUM 75.03% 1-Year Est. Return

BVF Inc's Q2 2025 Portfolio in Review

As of Q2 2025, BVF Inc held 52 positions worth $2.8B, up 14% from $2.45B the previous quarter. Its ten largest holdings account for 77% of the portfolio.

BVF Inc's Q2 2025 filing shows 1 new, 6 increased, 7 reduced and 8 closed positions. Its largest new stake was Immunocore: 1,024,288 shares worth $32.1M. The largest sale was Lakefront Biotherapeutics American Depositary Shares, an estimated $36.5M.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, up from 100% a quarter earlier, followed by Miscellaneous.

  • BVF Inc's largest Q2 2025 buy was Immunocore: 1,024,288 shares worth $32.1M.
  • BVF Inc added most to Protagonist Therapeutics in Q2 2025, an estimated $30.5M increase.
  • BVF Inc's biggest Q2 2025 reduction was Xoma, cutting an estimated $9.41M.
  • BVF Inc fully exited Lakefront Biotherapeutics American Depositary Shares in Q2 2025, selling an estimated $36.5M.
  • BVF Inc's ten largest holdings make up 77% of its $2.8B portfolio in Q2 2025.
  • BVF Inc opened 1 new position and closed 8 in Q2 2025.
  • BVF Inc's portfolio value rose 14% quarter-over-quarter to $2.8B.

Based on BVF Inc's 13F filing for Q2 2025, filed 14 Aug 2025.